0.2887
Sensei Biotherapeutics Inc stock is traded at $0.2887, with a volume of 543.84K.
It is down -11.25% in the last 24 hours and down -34.01% over the past month.
See More
Previous Close:
$0.3253
Open:
$0.3095
24h Volume:
543.84K
Relative Volume:
0.20
Market Cap:
$7.26M
Revenue:
-
Net Income/Loss:
$-29.80M
P/E Ratio:
-0.2426
EPS:
-1.19
Net Cash Flow:
$-25.19M
1W Performance:
-43.20%
1M Performance:
-34.01%
6M Performance:
-42.27%
1Y Performance:
-70.84%
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Name
Sensei Biotherapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SNSE
Sensei Biotherapeutics Inc
|
0.2887 | 7.26M | 0 | -29.80M | -25.19M | -1.19 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-14-24 | Initiated | Stephens | Overweight |
Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
Mar-01-21 | Initiated | Berenberg | Buy |
Mar-01-21 | Initiated | Citigroup | Buy |
Mar-01-21 | Initiated | Oppenheimer | Outperform |
Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Sensei Biotherapeutics Inc Stock (SNSE) Latest News
Penny Stocks To Add to Your WatchlistMarch 30th - MarketBeat
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - The Manila Times
Promising Penny Stocks To ResearchMarch 29th - MarketBeat
Best Penny Stocks To Follow NowMarch 28th - MarketBeat
Sensei Biotherapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa
Sensei Biotherapeutics stock hits 52-week low at $0.34 - Investing.com
HC Wainwright Reiterates Buy Rating for Sensei Biotherapeutics (NASDAQ:SNSE) - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Price Target Raised to $4.00 at Oppenheimer - Armenian Reporter
Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Sensei Biotherapeutics Reports Promising 2024 Results - TipRanks
Sensei Biotherapeutics (SNSE) Reports Annual Loss and Decline in Cash Reserves - GuruFocus
Sensei stock holds Buy rating, $4 target from H.C. Wainwright By Investing.com - Investing.com Australia
Sensei Rockets on FY ’24 Results - Baystreet.ca
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors - Benzinga
Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer - TipRanks
Oppenheimer Adjusts Price Target on Sensei Biotherapeutics to $4 From $3.50, Maintains Outperform Rating - Marketscreener.com
Sensei stock holds Buy rating, $4 target from H.C. Wainwright - Investing.com India
Sensei Biotherapeutics reports FY24 EPS ($1.20) vs ($1.22) last year - TipRanks
Sensei Biotherapeutics Inc Cash Runway Into Q2 Of 2026 - MarketScreener
Sensei Biotherapeutics, Inc. SEC 10-K Report - TradingView
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - GlobeNewswire
Breakthrough: Sensei's Cancer Drug Triples Response Rate in Hard-to-Treat Tumors - Stock Titan
Sensei Biotherapeutics announces initial results from solnerstotug trial portion - TipRanks
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data For Solnerstotug In PD-(L)1 Resistant Tumors - Marketscreener.com
Sensei Biotherapeutics : Company Presentation March 2025 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors - GlobeNewswire
Revolutionary Cancer Treatment Triples Response Rate in Hard-to-Treat Tumors: Clinical Trial Results Revealed - Stock Titan
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Large Drop in Short Interest - Defense World
Sensei Biotherapeutics Stock Price, Quotes and Forecasts | NASDAQ:SNSE - Benzinga
Sensei Biotherapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Sensei Biotherapeutics (SNSE) to Release Quarterly Earnings on Wednesday - Defense World
What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock - MSN
A stock that deserves closer examination: Sensei Biotherapeutics Inc (SNSE) - US Post News
Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference - The Manila Times
Biotech Spotlight: Sensei Bio Takes Center Stage at Major Healthcare Conference - StockTitan
Sensei Biotherapeutics, Inc. Appoints Robert Pierce as Chief Scientific Officer; Opens its Boston Office - Marketscreener.com
Sensei Biotherapeutics Inc Shares Rise 25.49% From The Lows – But Will They Continue? - Marketing Sentinel
Biotech Advances Breakthrough Cancer Treatment Results - Streetwise Reports
Sensei Biotherapeutics (NASDAQ:SNSE) Earns Buy Rating from HC Wainwright - Defense World
Sensei Biotherapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Australia
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones - The Manila Times
Sensei Bio's Cancer Drug Shows Promise in Phase 1/2 Trial, Enrolls 45 Patients for VISTA Study - StockTitan
Sensei Biotherapeutics faces Nasdaq delisting risk - Investing.com
Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference - GlobeNewswire
Sensei Biotherapeutics Q3 2024 Results and Strategic Moves - TipRanks
Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace
Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Sensei Biotherapeutics Inc. (SNSE) Quarterly 10-Q Report - Quartzy
Sensei Biotherapeutics Inc Stock (SNSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):